HRP20231015T1 - Upotreba antagonista il-13 u liječenju atopičnog dermatitisa - Google Patents
Upotreba antagonista il-13 u liječenju atopičnog dermatitisa Download PDFInfo
- Publication number
- HRP20231015T1 HRP20231015T1 HRP20231015TT HRP20231015T HRP20231015T1 HR P20231015 T1 HRP20231015 T1 HR P20231015T1 HR P20231015T T HRP20231015T T HR P20231015TT HR P20231015 T HRP20231015 T HR P20231015T HR P20231015 T1 HRP20231015 T1 HR P20231015T1
- Authority
- HR
- Croatia
- Prior art keywords
- dose
- lebrikizumab
- antibody against
- monoclonal antibody
- atopic dermatitis
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title claims 10
- 201000008937 atopic dermatitis Diseases 0.000 title claims 10
- 239000005557 antagonist Substances 0.000 title 1
- 229950002183 lebrikizumab Drugs 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000012423 maintenance Methods 0.000 claims 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u liječenju atopičnog dermatitisa kod pacijenta, naznačeno time što treba primijeniti najmanje jednu udarnu dozu, a najmanje jednu naknadnu dozu održavanja treba primijeniti supkutano, u ravnoj dozi, gdje je protutijelo protiv IL-13 lebrikizumab, te gdje (a) udarna doza je 250 mg, a doza održavanja je 125 mg, ili (b) udarna doza je 500 mg, a doza održavanja je 250 mg.
2. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je udarna doza 250 mg, a doza održavanja je 125 mg.
3. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je udarna doza 500 mg, a doza održavanja je 250 mg.
4. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što dozu održavanja treba primijeniti četiri tjedna nakon udarne doze, te što dozu održavanja treba primijeniti jednom svaka četiri tjedna nakon toga za vrijeme trajanja liječenja.
5. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što je trajanje liječenja 24 tjedna ili više.
6. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačeno time što lebrikizumab smanjuje težinu bolesti kod pacijenta, te što težinu bolesti treba procijeniti iz mjere ishoda težine bolesti atopičnog dermatitisa.
7. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 6, naznačeno time što je mjera ishoda težine bolesti atopičnog dermatitisa indeks površine i težina egzema (EASI), te što lebrikizumab smanjuje EASI za 50% ili 75% ili 90% u usporedbi s EASI kojeg treba odrediti prije primjene prve doze lebrikizumaba; gdje se EASI može odrediti 12 tjedana nakon primjene prve doze ili 20 tjedana nakon primjene prve doze ili 24 tjedna nakon primjene prve doze lebrikizumaba.
8. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 6, naznačeno time što je mjera ishoda težine bolesti atopičnog dermatitisa ocjenjivanje težine atopičnog dermatitisa (SCORAD), te što lebrikizumab smanjuje SCORAD za 50% ili 75% u usporedbi sa SCORAD kojeg treba odrediti prije primjene prve doze lebrikizumaba; gdje se SCORAD može odrediti 12 tjedana nakon primjene prve doze lebrikizumaba.
9. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 6, naznačeno time što je mjera ishoda težine bolesti atopičnog dermatitisa ispitivačeva globalna procjena (IGA), te što lebrikizumab smanjuje IGA na nulu ili jedan; gdje se IGA može odrediti 12 tjedana nakon primjene prve doze lebrikizumaba.
10. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 6, naznačeno time što je mjera ishoda težine bolesti atopičnog dermatitisa ishod kojeg prijavljuje pacijent (PRO), gdje je PRO (1) vizualna analogna skala svrbež (VAS), gdje lebrikizumab smanjuje svrbež VAS za 40% do 55%, (2) VAS gubitka sna, gdje lebrikizumab smanjuje VAS gubitka sna za 53% do 61%, ili (3) ocjena iz upitnika o utjecaju atopičnog dermatitisa (ADIQ), gdje lebrikizumab smanjuje ocjenu iz ADIQ za 54% do 65%; gdje se PRO može odrediti 12 tjedana nakon primjene prve doze lebrikizumaba.
11. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačeno time što lebrikizumab treba primijeniti na pacijentu uz pomoć uređaja za supkutanu primjenu, gdje se uređaj za supkutanu primjenu bira između prethodno napunjene štrcaljke, jednokratnom injekcijskom olovkom, uređaja s mikroiglom, mikroinfuzijskog uređaja, injekcijskog uređaja bez igle ili autoinjektora.
12. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačeno time što na pacijentu treba primijeniti jedan ili više topikalnih kortikosteroida.
13. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što se jedan ili više topikalnih kortikosteroida bira između triamcinolon-acetonida, hidrokortizona, ili kombinacije triamcinolon-acetonida i hidrokortizona.
14. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačeno time što je pacijent star 12 godina i više, i/ili što je pacijent neadekvatno kontroliran na topikalne kortikosteroide.
15. Monoklonsko protutijelo protiv IL-13, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačeno time što je atopični dermatitis umjeren do težak, što se utvrđuje iz ocjene prema Rajka/Langelandovim kriterijima, te što je određeno da je ocjena prema Rajka/Langelandovim kriterijima između 4,5 i 9.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398713P | 2016-09-23 | 2016-09-23 | |
| US201762527204P | 2017-06-30 | 2017-06-30 | |
| US201762530683P | 2017-07-10 | 2017-07-10 | |
| US201762539037P | 2017-07-31 | 2017-07-31 | |
| EP17780280.8A EP3528838B1 (en) | 2016-09-23 | 2017-09-22 | Uses of il-13 antagonists for treating atopic dermatitis |
| PCT/US2017/052891 WO2018057849A1 (en) | 2016-09-23 | 2017-09-22 | Uses of il-13 antagonists for treating atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231015T1 true HRP20231015T1 (hr) | 2023-12-08 |
Family
ID=60020628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231015TT HRP20231015T1 (hr) | 2016-09-23 | 2017-09-22 | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11434286B2 (hr) |
| EP (2) | EP3528838B1 (hr) |
| JP (1) | JP6995844B2 (hr) |
| KR (1) | KR102557643B1 (hr) |
| CN (1) | CN109715201A (hr) |
| AU (1) | AU2017330405B2 (hr) |
| CA (1) | CA3031589A1 (hr) |
| DK (1) | DK3528838T3 (hr) |
| ES (1) | ES2958593T3 (hr) |
| FI (2) | FI3528838T3 (hr) |
| HR (1) | HRP20231015T1 (hr) |
| HU (1) | HUE063135T2 (hr) |
| IL (1) | IL265473B2 (hr) |
| LT (1) | LT3528838T (hr) |
| MX (1) | MX2019002672A (hr) |
| NL (1) | NL301269I2 (hr) |
| PL (1) | PL3528838T3 (hr) |
| PT (1) | PT3528838T (hr) |
| RS (1) | RS64550B1 (hr) |
| RU (1) | RU2752785C2 (hr) |
| SG (1) | SG11201900845YA (hr) |
| SI (1) | SI3528838T1 (hr) |
| TW (1) | TWI787203B (hr) |
| UA (1) | UA124269C2 (hr) |
| WO (1) | WO2018057849A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124269C2 (uk) * | 2016-09-23 | 2021-08-18 | Дженентек, Інк. | Застосування антагоністу il-13 для лікування атопічного дерматиту |
| EP4126943A1 (en) * | 2020-03-23 | 2023-02-08 | MedImmune Limited | Methods for treating atopic dermatitis and related disorders |
| US20210301010A1 (en) * | 2020-03-23 | 2021-09-30 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| WO2022075476A1 (en) * | 2020-10-09 | 2022-04-14 | Kyowa Kirin Co., Ltd. | Method for treating ox40 related disease |
| AU2022238849A1 (en) | 2021-03-17 | 2023-08-31 | Receptos Llc | Methods of treating atopic dermatitis with anti il-13 antibodies |
| TW202317191A (zh) * | 2021-07-16 | 2023-05-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TW202323291A (zh) * | 2021-08-13 | 2023-06-16 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| CN118076636A (zh) * | 2021-09-15 | 2024-05-24 | 德米拉公司 | Il-13抑制剂用于治疗结节性痒疹 |
| WO2023215769A1 (en) * | 2022-05-05 | 2023-11-09 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
| WO2024054157A1 (en) * | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| PT1034298E (pt) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ATE303445T1 (de) | 1999-10-04 | 2005-09-15 | Medicago Inc | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| AU2002339845B2 (en) | 2001-08-03 | 2009-03-26 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| PT2805728T (pt) * | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
| JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック， インコーポレイテッド | ヒト化抗ＴＧＦ−β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| DK1737891T3 (da) | 2004-04-13 | 2013-03-25 | Hoffmann La Roche | Anti-p-selectin-antistoffer |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP2438948B1 (en) | 2004-11-24 | 2016-03-30 | SHL Group AB | Tubular rotator for a medicament injection device, and medicament injection device |
| ES2314568T3 (es) | 2005-06-01 | 2009-03-16 | Shl Group Ab | Dispositivo para la entrega de medicamento. |
| DK1885414T3 (da) | 2005-06-01 | 2013-02-11 | Shl Group Ab | Indretning til afgivelse af et lægemiddel |
| PL1942939T5 (pl) | 2005-09-30 | 2021-10-11 | Medimmune Limited | Kompozycja przeciwciała interleukiny-13 |
| WO2007045477A2 (en) * | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| AU2013204894B2 (en) * | 2010-12-16 | 2016-11-10 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| US9132236B2 (en) | 2011-06-17 | 2015-09-15 | Shl Group Ab | Injection device |
| CA2839493C (en) | 2011-06-17 | 2016-02-09 | Shl Group Ab | Injection device |
| FI3091029T3 (fi) * | 2011-10-31 | 2023-03-20 | Hoffmann La Roche | Anti-il13-vasta-aineformulaatioita |
| NZ731864A (en) | 2012-09-07 | 2022-07-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| MX2015013901A (es) | 2013-04-05 | 2015-12-11 | Genentech Inc | Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos. |
| KR20160113700A (ko) | 2014-01-27 | 2016-09-30 | 메디뮨 엘엘씨 | 천식 폐에서의 il-13 활성화의 말초 바이오마커로서의 디펩티딜 펩티다제-4(dpp4/cd26) |
| KR20170127011A (ko) | 2015-03-16 | 2017-11-20 | 제넨테크, 인크. | Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도 |
| UA124269C2 (uk) * | 2016-09-23 | 2021-08-18 | Дженентек, Інк. | Застосування антагоністу il-13 для лікування атопічного дерматиту |
-
2017
- 2017-09-22 UA UAA201902409A patent/UA124269C2/uk unknown
- 2017-09-22 HR HRP20231015TT patent/HRP20231015T1/hr unknown
- 2017-09-22 EP EP17780280.8A patent/EP3528838B1/en active Active
- 2017-09-22 PL PL17780280.8T patent/PL3528838T3/pl unknown
- 2017-09-22 DK DK17780280.8T patent/DK3528838T3/da active
- 2017-09-22 ES ES17780280T patent/ES2958593T3/es active Active
- 2017-09-22 RS RS20230712A patent/RS64550B1/sr unknown
- 2017-09-22 CN CN201780058200.4A patent/CN109715201A/zh active Pending
- 2017-09-22 JP JP2019515636A patent/JP6995844B2/ja active Active
- 2017-09-22 CA CA3031589A patent/CA3031589A1/en active Pending
- 2017-09-22 MX MX2019002672A patent/MX2019002672A/es unknown
- 2017-09-22 LT LTEPPCT/US2017/052891T patent/LT3528838T/lt unknown
- 2017-09-22 SI SI201731388T patent/SI3528838T1/sl unknown
- 2017-09-22 TW TW106132523A patent/TWI787203B/zh active
- 2017-09-22 HU HUE17780280A patent/HUE063135T2/hu unknown
- 2017-09-22 FI FIEP17780280.8T patent/FI3528838T3/fi active
- 2017-09-22 PT PT177802808T patent/PT3528838T/pt unknown
- 2017-09-22 AU AU2017330405A patent/AU2017330405B2/en active Active
- 2017-09-22 EP EP23182855.9A patent/EP4268845A3/en active Pending
- 2017-09-22 IL IL265473A patent/IL265473B2/en unknown
- 2017-09-22 KR KR1020197007162A patent/KR102557643B1/ko active IP Right Grant
- 2017-09-22 SG SG11201900845YA patent/SG11201900845YA/en unknown
- 2017-09-22 RU RU2019103943A patent/RU2752785C2/ru active
- 2017-09-22 WO PCT/US2017/052891 patent/WO2018057849A1/en active Application Filing
-
2019
- 2019-03-18 US US16/356,309 patent/US11434286B2/en active Active
-
2022
- 2022-08-08 US US17/882,932 patent/US20220372131A1/en active Pending
-
2024
- 2024-04-29 NL NL301269C patent/NL301269I2/nl unknown
- 2024-04-30 FI FIC20240013C patent/FIC20240013I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231015T1 (hr) | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa | |
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| JP2019533646A5 (hr) | ||
| JP2016540785A5 (hr) | ||
| ES2362525B8 (es) | Formulación de medicamentos en forma de agujas percutaneas penetrantes. | |
| BR112016000177A2 (pt) | usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta | |
| CL2018000002A1 (es) | Agente terapéutico y método para tratar el síndrome de hunter. | |
| GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
| BR112017021383A2 (pt) | regime de dosagem para doses omitidas de ésteres de paliperidona injetáveis de longa ação | |
| WO2014036556A3 (en) | Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine | |
| MX2015005879A (es) | Formulaciones de capsaicinoides basadas en agua, y tratamiento en combinacion con un corticosteroide. | |
| Farsi et al. | Acute pain management with intravenous 0.10 mg/kg vs. 0.15 mg/kg morphine sulfate in limb traumatized patients: a randomized double-blinded placebo-controlled trial | |
| JP2013520447A5 (hr) | ||
| Tabeeva et al. | The multimodal strategy for the neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL | |
| IL310706A (en) | IL-13 antibodies for the treatment of atopic dermatitis | |
| BR112017022984A2 (pt) | dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| Elliot et al. | Therapeutic benefits of exosomes derived from mesenchymal stromal cells in bleomycin-induced pulmonary fibrosis in aged mice | |
| Park et al. | Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion | |
| Elliott et al. | Ixekizumab Injection (Taltz) | |
| Ram et al. | Giant Papillae in Vernal Keratoconjunctivitis | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| Corno et al. | 033 Effect of testosterone on vaginal function in an experimental rat model | |
| Luo | Cochrane Review Brief: Chinese Herbal Medicine for Endometriosis. | |
| White | The hypodermic syringe and the rise of addiction |